First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Ginkgo Bioworks Holdings, Inc.

    DNA · 9 developments mapped · last assessed 2026-09-25

    Market Ontology has mapped 9 macro, policy, and market developments to Ginkgo Bioworks Holdings, Inc. since 2026-09-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for DNA yet, so no modelled value is shown. The DNA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run DNA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for DNA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants

      Direct revenue generation from new contract, validation of platform technology, potential for future partnerships.

      · Moves revenue growth rate, customer acquisition rate, platform validation

    • Open question

      Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact

      Increased investor attention on synthetic biology and AI in drug discovery, competitive landscape implications.

      · Moves market growth for synthetic biology services, competitive positioning

    What changed, by assumption

    Revenue growth rate
    • 2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
    Customer acquisition rate
    • 2026-09-25Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D Expands
    • 2026-09-25Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JV
    Contract win rate
    • 2026-09-25Pfizer and NVIDIA invest $80M in CytoReason JV as vaccine AI funding tops $140M
    Market growth for synthetic biology platforms
    • 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReason
    Investor sentiment
    • 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReasonBullish1-3m0.40
    2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine AdjuvantsBullish1-3m0.70
    2026-09-25Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JVBullish1-3m0.60
    2026-09-25Pfizer and NVIDIA invest $80M in CytoReason JV as vaccine AI funding tops $140MBullish1-3m0.70
    2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine DiscoveryBullish1-3m0.40
    2026-09-25Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D ExpandsBullish1-3m0.70
    2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactmixed1-3m0.40
    2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discoverywatch1-3m0.30
    2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discoverymixed1-3m0.30